SHANG.FOS.PHARM.GR.H YC 1 (08HH) — Cash Flow Reinvestment Rate
SHANG.FOS.PHARM.GR.H YC 1 (08HH) has a Cash Flow Reinvestment Rate of 1.30x as of December 2025, reinvesting €6.75 Billion (capex €4.45 Billion plus investments €2.31 Billion) from operating cash flow of €5.21 Billion. See 08HH FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
SHANG.FOS.PHARM.GR.H YC 1 Cash Flow Reinvestment Rate (2021–2025)
Historical reinvestment intensity for SHANG.FOS.PHARM.GR.H YC 1 across 5 annual periods. For the full cash flow conversion analysis, see SHANG.FOS.PHARM.GR.H YC 1 operating cash flow efficiency.
Annual Cash Flow Reinvestment Rate for SHANG.FOS.PHARM.GR.H YC 1 (2021–2025)
Year-by-year capital reinvestment analysis for SHANG.FOS.PHARM.GR.H YC 1. See 08HH financial flexibility score to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.30x | €6.75 Billion | €5.21 Billion | €4.45 Billion | ▲ +14.6% |
| 2024 | 1.13x | €5.06 Billion | €4.48 Billion | €4.41 Billion | ▼ -46.4% |
| 2023 | 2.11x | €7.20 Billion | €3.41 Billion | €5.34 Billion | ▼ -1.5% |
| 2022 | 2.14x | €9.04 Billion | €4.22 Billion | €5.89 Billion | ▲ +47.6% |
| 2021 | 1.45x | €5.72 Billion | €3.94 Billion | €4.97 Billion | — |